HealthCap highlighted Hemab presenting new clinical data and introducing HMB-003 at ISTH 2026.
Hemab Therapeutics is focused on developing targeted therapies for bleeding disorders, including Glanzmann Thrombasthenia and Von Willebrand Disease, aiming to provide new treatment options for patients with significant life-long disease burdens
Hemab Therapeutics is focused on developing targeted therapies for bleeding disorders, including Glanzmann Thrombasthenia and Von Willebrand Disease, aiming to provide new treatment options for patients with significant life-long disease burdens.